250 related articles for article (PubMed ID: 9118380)
1. Proper staging techniques in testicular cancer patients.
Moul JW
Tech Urol; 1995; 1(3):126-32. PubMed ID: 9118380
[TBL] [Abstract][Full Text] [Related]
2. Neural network analysis of quantitative histological factors to predict pathological stage in clinical stage I nonseminomatous testicular cancer.
Moul JW; Snow PB; Fernandez EB; Maher PD; Sesterhenn IA
J Urol; 1995 May; 153(5):1674-7. PubMed ID: 7715008
[TBL] [Abstract][Full Text] [Related]
3. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors.
Fernandez EB; Moul JW; Foley JP; Colon E; McLeod DG
Urology; 1994 Oct; 44(4):548-52. PubMed ID: 7941194
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of radiographic chest imaging in patients with testicular cancer.
Fernandez EB; Colon E; McLeod DG; Moul JW
Urology; 1994 Aug; 44(2):243-8; discussion 248-9. PubMed ID: 8048200
[TBL] [Abstract][Full Text] [Related]
5. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer.
Moul JW; McCarthy WF; Fernandez EB; Sesterhenn IA
Cancer Res; 1994 Jan; 54(2):362-4. PubMed ID: 8275469
[TBL] [Abstract][Full Text] [Related]
6. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
[TBL] [Abstract][Full Text] [Related]
7. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
[TBL] [Abstract][Full Text] [Related]
8. Imaging of the thorax in the management of germ cell testicular tumours.
White PM; Adamson DJ; Howard GC; Wright AR
Clin Radiol; 1999 Apr; 54(4):207-11. PubMed ID: 10210337
[TBL] [Abstract][Full Text] [Related]
9. Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
Williams SB; McDermott DW; Dock W; Bahnson E; Berry AM; Steele GS; Richie JP
J Urol; 2009 May; 181(5):2097-101; discussion 2101-2. PubMed ID: 19286227
[TBL] [Abstract][Full Text] [Related]
10. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ
Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612
[TBL] [Abstract][Full Text] [Related]
11. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
12. Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.
Joice GA; Rowe SP; Gorin MA; Pierorazio PM
Curr Urol Rep; 2018 Nov; 19(12):110. PubMed ID: 30413968
[TBL] [Abstract][Full Text] [Related]
13. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
14. [Histopathologic and biological prognostic factors of clinical stage I non-seminomatous germ cell tumors. Implications for risk-adjusted therapy].
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW; Engelmann UH
Urologe A; 1999 Mar; 38(2):168-78. PubMed ID: 10231939
[TBL] [Abstract][Full Text] [Related]
15. Role of lymphangiography in staging testicular seminoma.
Marks LB; Shipley WU; Walker TG; Waltman AC
Urology; 1991 Sep; 38(3):264-6. PubMed ID: 1887542
[TBL] [Abstract][Full Text] [Related]
16. Metastases of clinically occult testicular seminoma mimicking primary extragonadal retroperitoneal germ cell tumors.
Coulier B; Lefebvre Y; de Visscher L; Bourgeois A; Montfort L; Clausse M; Mailleux P; Gielen I
JBR-BTR; 2008; 91(4):139-44. PubMed ID: 18817085
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma.
Seelemeyer F; Pfister D; Pappesch R; Merkelbach-Bruse S; Paffenholz P; Heidenreich A
Eur Urol Oncol; 2024 Jun; 7(3):319-322. PubMed ID: 37932157
[TBL] [Abstract][Full Text] [Related]
18. Reliability of diagnostic imaging after orchiectomy alone in follow-up of clinical stage I testicular carcinoma: excessive cost with potential risk.
Tesoro-Tess JD; Pizzocaro G; Zanoni F; Balzarini L; Ceglia E; Petrillo R; Musumeci R
Lymphology; 1987 Sep; 20(3):161-5. PubMed ID: 3682940
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis.
Albers P; Miller GA; Orazi A; Ulbright TM; Albers J; Donohue JP; Foster RS
Cancer; 1995 Feb; 75(3):844-50. PubMed ID: 7828136
[TBL] [Abstract][Full Text] [Related]
20. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
